Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Small bios have little chance of changing the WS street narrative even with spectacular trial results. I think we have seen that with our success in every single trial. I agree, We Got This but when are the hundreds of thousands of people that could benefit from from what we got going to Get It?
Dr Missling has accomplished great things for our company. It seems now we need a partnership with a deep pocketed, well established bio (not biib) to bring this forward. I know this is not what Dr Missling wanted but this is what needs to happen, IMO.
“Id just say LEADERSHIP needs major redo”
I agree if Fraudstein is the one you are talking about. Shorting at this time is like jumping off a cliff. With our successful Phase 3 Rett Disease trial, our sp is set for rapid increase. Nobody knows more than the parents and caregivers of these girls and women that the time for effective treatment with a remarkable safety profile is long overdue. Don’t underestimate what Missling and his team have accomplished. The time for being on the fence whether to invest in this massive growth opportunity has passed, IMO.
Hunter Biden’s father has recently begun talking about pill vaccine for the booster. No company names mentioned though.
He also just completed a successful Phase 3 trial that will bring real relief to a suffering community and their families and caregivers. The initial endpoints indicated but did not prove efficacy but possibly could have led to FDA approval. Doctor Missling did say the change narrowed the goal posts but came about during the course of meetings with the FDA. Missling has a lot on his plate. These enhanced endpoints were discussed and implemented before Phase 3 data was available and well before publication. Einstein was unable to drive a car. Maybe we should stand behind Dr Missling. We Still Got This.
Not sure if this has been posted already:
https://www.neurologylive.com/view/blarcamesine-shows-promise-potential-rett-syndrome-treatment-new-data-indicate
I always thought Fraudstein was head of a short seller group but who knows. 2 of Biogen’s BOD members are resigning Feb 3. One of their main aduhelm doctors resigned in December. Now Biogen is looking for companies to take over:
https://www.fiercepharma.com/pharma/biogen-compiles-buyout-target-list-as-aduhelm-woe-deepens-stat
When word got out that vaccinated folks could still get and shed the virus, common sense told me that the unmasked vaccinated folks could potentially be super-spreaders of the virus. As an N95 masked, unvacced individual, I avoided isles in the grocery store with large groups of shoppers, especially early on up through the Delta variant. I believe in natural immunity, so when the less harmful Omicron variant came along, I put my N95
aside and attended a gathering with an unmasked, vaxxed group and I got Omicron. In 5 days or so, I fully recovered. I still wear my N95 but feel pretty well protected against the newer Omicron and other variants because of my natural immunity. I’m not anti-vax for others but I am for me.
Thanks for your hard work and dedication to AVXL.
Th real culprit in the degradation of the share price is Climate Change. But you know that.
Thank you for the link. It highlights our current situation and helps explain why we seem to be in what seems an endless delay in data-rich announcements. Our CEO has experienced a frivolous lawsuit early on in our company’s history. I believe “we got this.” Time to give our CEO a break.
EXPECT ABSOLUTELY GREAT NEWS REGARDING AVXL TOMORROW!!!
Good luck and GOD bless
Sorry. Couldn’t help myself. But just think about it. If Dr Missling unloaded several data rich announcements, we would witness the long overdue payback time for the market manipulators.
If the sp approaches $10, I will sell some of my other holdings and load up. No anger here either.
Sorry for the loss of your dad, D-Mike. My dad left us 17 years ago tomorrow. It’s still hurts. Hopefully, the efforts being put forth here will help bring an end to CNS disease.
I was invested in BIIB years ago. Sold all at about $475 per share and bought a boatload here at 17 cents. One of my best investment decisions.
Thanks for providing a clear path for those considering whether to climb aboard this Anavex train. I don’t post much here anymore but totally agree with why we longer timers stay here. It was certainly more of a gamble when I first came on board at 17 cents. Today, I see my investment here as a sound investment. But I do continue to watch this story unfold and I continue to put my trust in the competence of our CEO. Do I hope to make a few more dollars here? Of course.The joy of bringing a new product to market that helps people to live better lives is not new to me. I look forward to that day. Thanks for your post.
Just to be clear, the 17% drop out you are referring to is from the Acadia phase 3 trial not from any Anavex trials.
Thanks Falconer. Makes sense. We should have enough data to show efficacy for any of the diseases we have ongoing trials for. Existing vaccines for Covid-19 are not true vaccines. Vaccines, in my day, prevented and eradicated diseases. These so-called vaccines for covid create super spreaders shedding the virus to no end. Our 2-73 needs to move toward approval now. It may just find a home for other diseases, maybe even Covid. These vaccines are junk. All my opinion.
Alzheimer’s Disease and Dementia finally taking center stage once again:
https://finance.yahoo.com/news/thousands-join-walk-end-alzheimers-132044268.html
Here are the short cybn sales greater than or equal to $5000 per trade, traded in the last 7 days. Looks to me it may be a massively higher percent than what it was on Oct 15th. If news is wildly good, we could see a short squeeze. Hope so.
https://fintel.io/sst/us/cybn
Agreed. His interview skills are amazing. Thanks for the link.
Nobody Home?
Big News potentially coming Monday before the market opens (8:30 - 9:30 A.M.)
https://finance.yahoo.com/news/cybin-hosting-research-development-briefing-110000013.html
Thanks for the post, Investor2014. I listened to the entire Podcast. Interesting. It is and has been my position that antivirals could be the answer to this pandemic. It is encouraging that Pfizer seems headed in that direction. The guest in the podcast doesn’t pass the bs test for me. Glad we have a ceo here with the curiosity and courage to think outside of the box to find a real solution to cns disease.
YiqiHuoxue decoction (YHD) is frequently prescribed to treat Qi deficiency and blood stasis of coronary heart disease in clinical practice to ameliorate a patient’s symptoms and enhance their quality of life. YHD is derived from extracts of Panax ginseng, Astragalus mongholicus, Radix Paeoniae Rubra, and Carthamus tinctorius.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760134/
Rolling BLA Submission?
Amyloid Placqe removal seems to be the new thumbs up proof of efficacy. Sad.
From Alzheimers’s News Today:
https://alzheimersnewstoday.com/2021/10/04/eisai-starting-fda-submission-alzheimers-therapy-lecanemab/?utm_source=ALZ&utm_campaign=cea7439142-RSS_EMAIL_CAMPAIGN_US&utm_medium=email&utm_term=0_94425accb7-cea7439142-71376045
Looks like we are moving center stage:
https://finance.yahoo.com/news/cybin-announces-appointment-dr-amir-110000421.html
Looks like we will be moving center stage:
https://finance.yahoo.com/news/cybin-announces-appointment-dr-amir-110000421.html
The investor side of me calls for a more favorable share price to rise in acknowledgment of the favorable results of all 3 of our clinical trials.
The medical side of me calls for a more accelerated path to approval for these unmet needs.
With the reported CNS side effects from the upcoming mandated vax, a growing population of unmet needs could be upon us. Someone from stocktwits board said one of the CNS side effects resembles Rett Syndrome. We may have an answer for that but first we need approval for one of the 3.
If we had “solid IP protection all along” why would we need reinforcement? This should end any future discussion on 2-73 patent protection issues. It’s all good.
Now that we gained a solid patent approval, hopefully, Dr Missling will more aggressively pursue the FDA to skip Phase 3 for Alzheimer’s or Rhett Syndrome and continue trials after market approval. We.should at least be seeing a more steady flow of PRs.
Alzheimer’s Disease Biomarkers present in some COVID-19 Patients
Could A2-73 have a role here?
https://alzheimersnewstoday.com/2021/08/09/alzheimers-disease-biomarkers-present-some-covid-19-patients/?utm_source=ALZ&utm_campaign=38b1014b37-RSS_EMAIL_CAMPAIGN_US&utm_medium=email&utm_term=0_94425accb7-38b1014b37-71376045
I have no doubt A-273 will become a life changing drug. We already have good response in AD, PDD and Rett Syndrome. Approval for any one of those diseases will allow off label prescriptions. The new trial will no doubt include in depth data collection that will likely identify other positive responses to a multitude of yet unknown
ailments leading to additional off label use. Most disease processes begin with inflammation. Our drug reduces inflammation, restores homeostasis and does a multitude of other things. Approval for any of the three ongoing trial diseases will be a game changer. All my opinion.
Neurodevelopmental Disorders
Another good use of capital.
https://www.epa.gov/sites/default/files/2015-10/documents/ace3_neurodevelopmental.pdf
This is a very wise move. A273 restores homeostasis. AD is just one of a number of CNS diseases that it may benefit. Cardiac and eye disease can indirectly be added to the mix of disease. This really amounts to a basket of disease trial. The participants in the trial should certainly prove to be a healthier group than the general population. It is a wise use of capital and goes far beyond AD, IMO.
Seems to me AAiC has become a platform for spreading false hope with Biogen appropriately one of its main sponsors. Anavex isn’t in that game. Restoring homeostasis upstream of the disease process takes care of the tangles and amyloid plaque that other bios are once again focusing on. Our decision to refrain from participating in the AAIC shtshow is a good thing, IMO.
Great find. Thank you!
An interesting perspective, perhaps: